MedKoo Cat#: 463717 | Name: Resorcinolnaphthalein
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Resorcinolnaphthalein is an Angiotensin-converting enzyme 2 (ACE2) activator, acting as a modulator on RAAS and KKS activation during COVID-19.

Chemical Structure

Resorcinolnaphthalein
Resorcinolnaphthalein
CAS#41307-63-5

Theoretical Analysis

MedKoo Cat#: 463717

Name: Resorcinolnaphthalein

CAS#: 41307-63-5

Chemical Formula: C24H14O5

Exact Mass: 382.0841

Molecular Weight: 382.37

Elemental Analysis: C, 75.39; H, 3.69; O, 20.92

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 2 Weeks
10mg USD 400.00 2 Weeks
50mg USD 700.00 2 Weeks
100mg USD 1,000.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Resorcinolnaphthalein; NSC-354317; NSC354317; NSC 354317;
IUPAC/Chemical Name
3',6'-dihydroxy-3H-spiro[benzo[de]isochromene-1,9'-xanthen]-3-one
InChi Key
FTUOFHGOGJGQAB-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H14O5/c25-14-7-9-17-20(11-14)28-21-12-15(26)8-10-18(21)24(17)19-6-2-4-13-3-1-5-16(22(13)19)23(27)29-24/h1-12,25-26H
SMILES Code
O=C(OC12C3=C(OC4=C2C=CC(O)=C4)C=C(O)C=C3)C5=CC=CC6=C5C1=CC=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Resorcinolnaphthalein increases the activity of ACE2 in vitro (EC50 = 19.5 μM). The activation of ACE2 in rats decreases blood pressure and improves cardiac function. In spontaneously hypertensive rats it produces a reversal of myocardial, perivascular, and renal fibrosis.
In vitro activity:
In vitro assays revealed that resorcinolnaphthalein enhanced ACE2 activity in a dose-dependent manner. Compounds that activate ACE2 lead to decreased blood pressure and the reversal of tissue remodeling. Administration of ACE2 activators has potential for antihypertensive therapy. Reference: Hypertension. 2008 May;51(5):1312-7. https://pubmed.ncbi.nlm.nih.gov/18391097/
In vivo activity:
Resorcinolnaphthalein significantly reduced the severity of acute lung injury (ALI) and pyroptosis in a mice model of ALI. Additionally, resorcinolnaphthalein significantly decreased NLRP3 levels. NLRP3 knockout significantly reduced the severity of ALI and pyroptosis. Reference: Arch Biochem Biophys. 2020 Oct 30;693:108562. https://pubmed.ncbi.nlm.nih.gov/32866470/
Solvent mg/mL mM
Solubility
DMSO 30.0 78.46
DMF 30.0 78.46
Ethanol 20.0 52.31
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 382.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097. 2. Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470. 3. Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157.
In vitro protocol:
1. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097.
In vivo protocol:
1. Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470. 2. Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157.
1: Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470. 2: Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020 Jul;157:104833. doi: 10.1016/j.phrs.2020.104833. Epub 2020 Apr 14. PMID: 32302706; PMCID: PMC7194807. 3: Zhang X, Zheng J, Yan Y, Ruan Z, Su Y, Wang J, Huang H, Zhang Y, Wang W, Gao J, Chi Y, Lu X, Liu Z. Angiotensin-converting enzyme 2 regulates autophagy in acute lung injury through AMPK/mTOR signaling. Arch Biochem Biophys. 2019 Sep 15;672:108061. doi: 10.1016/j.abb.2019.07.026. Epub 2019 Jul 26. PMID: 31356776. 4: Yan D, Li G, Zhang Y, Liu Y. Angiotensin-converting enzyme 2 activation suppresses pulmonary vascular remodeling by inducing apoptosis through the Hippo signaling pathway in rats with pulmonary arterial hypertension. Clin Exp Hypertens. 2019;41(6):589-598. doi: 10.1080/10641963.2019.1583247. Epub 2019 Feb 26. PMID: 30806090. 5: Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157. 6: Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, Li Z, Su J, Sun L. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013 Aug;191(4):327-36. doi: 10.1007/s00408-013-9470-8. Epub 2013 May 8. PMID: 23652350. 7: Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL. Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J (Engl). 2012 Apr;125(8):1381-8. PMID: 22613639. 8: Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097.